GSK plc Buys Back Own Shares

Ticker: GLAXF · Form: 6-K · Filed: May 15, 2025 · CIK: 1131399

Gsk PLC 6-K Filing Summary
FieldDetail
CompanyGsk PLC (GLAXF)
Form Type6-K
Filed DateMay 15, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: share-buyback, stock-repurchase

Related Tickers: GSK

TL;DR

GSK is buying back its own stock via Citigroup.

AI Summary

GSK plc announced on May 15, 2025, that it has purchased a number of its own ordinary shares through its corporate stockbroker, Citigroup Global Markets Limited. The filing does not specify the exact number of shares or the total dollar amount of the transaction.

Why It Matters

Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.

Risk Assessment

Risk Level: low — This is a routine disclosure of share repurchases, which is common for publicly traded companies.

Key Players & Entities

  • GSK plc (company) — The company making the share purchase.
  • Citigroup Global Markets Limited (company) — The corporate stockbroker acting on behalf of GSK plc.
  • May 2025 (date) — The reporting period for the transaction.

FAQ

What is the specific number of GSK plc ordinary shares purchased?

The filing states that a 'number' of ordinary shares were purchased, but does not specify the exact quantity.

What is the total dollar amount spent on the share repurchase?

The filing does not disclose the total dollar amount of the share repurchase.

When did the share repurchase transaction occur?

The transaction is reported for the month of May 2025.

Who is acting as GSK plc's corporate stockbroker for this transaction?

Citigroup Global Markets Limited is acting as GSK plc's corporate stockbroker.

What is the par value of GSK plc's ordinary shares?

The ordinary shares have a par value of 31 1/4 pence each.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on May 15, 2025 regarding GSK plc (GLAXF).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.